Has Maen Hussein, MD received payments from drug or device companies?

Yes. Drug and device makers reported $18,350,939 in general payments to Maen Hussein, MD across 2,937 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Maen Hussein, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Maen Hussein, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Maen Hussein, MD

Medical Oncology · Tavares, FLNPI 1356332506

Payments from drug & device makers

$18,350,939in general payments, 2019–2025

Across 2,937 payments — averaging $6248.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Astrazeneca UK Limited$8.9M
Genentech, Inc.$2M
AstraZeneca$1.7M
Aadi Bioscience, Inc.$1.1M
E.r. Squibb & Sons, L.L.C.$1M
Boehringer Ingelheim International GmbH$676K
plus $2.9M from 54 others

$25,052in research payments, 2019–2025

Across 17 payments — averaging $1473.67 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Pfizer$17K
F. Hoffmann-la Roche AG$5K
Eli Lilly$2K
Bristol Myers Squibb$1K

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Astrazeneca UK Limited	22	$8,907,454
Genentech, Inc.	287	$2,037,306
AstraZeneca(2 entities)	194	$1,707,275
Aadi Bioscience, Inc.	62	$1,095,506
E.r. Squibb & Sons, L.L.C.	98	$1,046,183
Boehringer Ingelheim International GmbH	576	$675,737
Ipsen Bioscience Inc.	93	$514,685
Array Biopharma Inc	109	$432,423
Merck	131	$296,920
F. Hoffmann-la Roche AG	38	$275,725
EMD Serono, Inc.	31	$266,963
Mirati Therapeutics, Inc.	57	$227,594
Beigene, Ltd.	67	$210,226
Clovis Oncology, Inc.	32	$191,218
G1 Therapeutics, Inc.	51	$184,428
GSK	55	$59,884
Eli Lilly	14	$44,097
Pfizer	103	$39,132
Johnson & Johnson	89	$24,088
Beone Medicines Ltd.	7	$17,350
Ipsen Biopharmaceuticals, Inc	20	$14,232
Bristol Myers Squibb	51	$12,267
Bayer	34	$5,036
AbbVie	21	$4,737
Lilly USA, LLC	32	$3,987
Morphosys, US Inc.	10	$3,841
Sanofi	31	$3,747
Daiichi Sankyo Inc.	30	$3,591
Stemline Therapeutics Inc.	7	$3,304
Karyopharm Therapeutics Inc.	6	$3,126
Beigene USA, Inc.	15	$2,985
Pharmaessentia USA Corporation	5	$2,918
Incyte Corporation	42	$2,756
Genentech USA, Inc.	45	$2,613
Janssen Scientific Affairs, LLC	2	$2,533
Athenex Pharmaceutical Division, LLC	2	$2,420
Novartis	62	$2,264
Adaptive Biotechnologies Corporation	9	$1,983
AVEO Pharmaceuticals, Inc.	5	$1,884
Azurity Pharmaceuticals, Inc.	1	$1,875
Exelixis Inc.	4	$1,611
Beone Medicines USA, Inc.	7	$1,284
Jazz Pharmaceuticals Inc.	10	$1,259
CTI Biopharma Corp.	5	$1,160
Gilead(2 entities)	39	$1,055
Amgen	46	$809
Eisai Inc.	35	$743
Seagen Inc.	38	$658
Pharmacyclics LLC, An Abbvie Company	30	$646
Boehringer Ingelheim Pharma GmbH & Co.kg	2	$511
ADC Therapeutics America, Inc.	6	$440
Astellas Pharma US Inc	17	$389
Octapharma USA, Inc.	2	$332
Blueprint Medicines Corporation	5	$315
Cvrx, Inc.	2	$288
Rigel Pharmaceuticals, Inc.	10	$268
Regeneron Healthcare Solutions, Inc.	9	$232
Takeda Pharmaceuticals U.S.A., Inc.	10	$225
Foundation Medicine, Inc.	6	$211
Boehringer Ingelheim	9	$162

How this compares

$18,350,939 in reported general payments places this provider in the 95th percentile of 507 medical oncology providers in Florida.

See all medical oncology providers in Florida →

Medicare billing

Part B allowed, 2024

$10,720,515

Medicare patients

2,085

Services billed

538,934

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other medical oncology in Tavares

Zeynep ErogluTampa$30.9M
Manish PatelSarasota$29.7M
Jad ChahoudTampa$21.8M
Patrick HwuTampa$18M
Gail WrightHudson$13.8M
Adil DaudTampa$13.3M
Lowell HartFort Myers$10.1M
Judy WangSarasota$9.8M
Jonathan StrosbergTampa$9.7M
Jennifer CultreraLady Lake$9.2M

See the full list for Florida →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →